[{"orgOrder":0,"company":"HEC Group","sponsor":"Lannett Company, Inc.","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Hormone","year":"2021","type":"Collaboration","leadProduct":"Insulin aspart","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"HEC Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"HEC Group \/ Lannett Company, Inc.","highestDevelopmentStatusID":"1","companyTruncated":"HEC Group \/ Lannett Company, Inc."}]

Find Clinical Drug Pipeline Developments & Deals by HEC Group

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Peptide-Based Therapeutics Summit
                          Not Confirmed
                          Peptide-Based Therapeutics Summit
                          Not Confirmed

                          Details :

                          Product Name : Undisclosed

                          Product Type : Hormone

                          Upfront Cash : Undisclosed

                          September 02, 2021

                          Lead Product(s) : Insulin aspart

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Undisclosed

                          Sponsor : Lannett Company, Inc.

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank